Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17633933 | 0.75 | KMT2A (0.77) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10330811 | 0.70 | DNMT1 (0.53) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10767199 | 0.69 | ALDH1A1 (0.52) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6987050 | 0.69 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12744425 | 0.68 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10404244 | 0.68 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7140573 | 0.67 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10404243 | 0.67 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10403758 | 0.67 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10403761 | 0.67 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-20220347126-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021203136-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-10905660-B2 | Microparticles | NOVABIOTICS LIMITED (GB) | 2021-02-02 | — | — | US | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4139635-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1979-02-13 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-4035492-A | Oral treatment of seborrhea with cysteamine derivatives | L'OREAL (FR) | 1977-07-12 | — | — | US | disclosed |
| US-3976781-A | SULFUR CONTAINING AMINES | L'OREAL (FR) | 1976-08-24 | — | — | US | disclosed |
| US-3950542-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | ALDH1A1 2213/4885LMNA 3342/4885SMN1; SMN2 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.